Declan T. Chard

Sep 3, 2024 | nature.com | Ruth Geraldes |Georgina Arrambide |Alex Rovira |Hans Lassmann |Patrick Waters |Declan T. Chard | +6 more

AbstractMyelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is an immune-mediated demyelinating disease that is challenging to differentiate from multiple sclerosis (MS), as the clinical phenotypes overlap, and people with MOGAD can fulfil the current MRI-based diagnostic criteria for MS. In addition, the MOG antibody assays that are an essential component of MOGAD diagnosis are not standardized.

Sep 15, 2023 | journals.sagepub.com | Declan T. Chard

In this issue of the Multiple Sclerosis Journal, Boccia et al.1 provide a timely reminder that grey matter lesions, while a clinically significant element of MS pathology, are not MS-specific. They report on a person with MS found to have an atrial myxoma after developing multiple cortical grey matter lesions (initially seen on a routine treatment monitoring magnetic resonance imaging (MRI)) while on ocrelizumab.